Drug
Emapalumab clinical trials
Also written NI-0501 and Gamifant.
- studies test it
- 21
- open now
- 10
- in phase 3
- 6
- first study started
- 2011
Keep track of what changes. Save the Emapalumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 14
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 10
Swedish Orphan Biovitrum (11) · Children's Healthcare of Atlanta (1) · NYU Langone Health (1) · University of California, San Francisco (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Miami (1) · M.D. Anderson Cancer Center (1) · City of Hope Medical Center (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Fludarabine (1) · Dexamethasone (1) · Interleukin 1 Receptor Antagonist Protein (1)
Studies
Open first, then newest update. How each study uses Emapalumab is read from its arms, and is right about nine times in ten.
Testing it · 21
- Randomized Stepped Wedge Study of Emapalumab in APECED EnteritisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07202598Written as Emapalumab
- Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) StudyRecruitingPhase 2University of MiamiNCT07486869Written as Emapalumab
- A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged CytopeniaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06285825Written as Emapalumab
- Severe Hepatitis Intervention With Emapalumab for Liver DiseaseNot yet recruitingPhase 2Children's Healthcare of AtlantaNCT07744919Written as Emapalumab
- Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06996119Written as Emapalumab
- A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionRecruitingPhase 2Joseph OvedNCT05787574Written as Emapalumab
- Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSNot yet recruitingPhase 2NYU Langone HealthNCT07567014Written as Emapalumab
- Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionNot yet recruitingPhase 2University of California, San FranciscoNCT07538336Written as Emapalumab
- Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) RecipientsRecruitingEarly Phase 1Children's Hospital Medical Center, CincinnatiNCT07244419Written as Emapalumab 3 mg/kg
- A Study of Emapalumab for Pediatric Aplastic AnemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06430788Written as Emapalumab
- A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese PatientsCompletedPhase 4Swedish Orphan BiovitrumNCT05744063Written as Emapalumab-Lzsg 5 MG/ML [Gamifant]
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedPhase 3Swedish Orphan BiovitrumNCT05001737Written as Emapalumab
- Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic LymphohistiocytosisCompletedPhase 3Swedish Orphan BiovitrumNCT03312751Written as Emapalumab
- Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.TerminatedPhase 2Swedish Orphan BiovitrumNCT04731298Written as Emapalumab
- A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.CompletedPhase 1Swedish Orphan BiovitrumNCT04765553Written as NI-0501
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLHTerminatedPhase 2/3Swedish Orphan BiovitrumNCT03985423Written as Emapalumab-Lzsg
- First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy VolunteersCompletedPhase 1Swedish Orphan BiovitrumNCT01459562Written as NI-0501
- Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisCompletedPhase 2/3Swedish Orphan BiovitrumNCT01818492Written as NI-0501
- A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal AntibodyCompletedPhase 2/3Swedish Orphan BiovitrumNCT02069899Written as Emapalumab
- A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)CompletedPhase 2Swedish Orphan BiovitrumNCT03311854Written as Emapalumab
See all 21 studies that test Emapalumab →
Given in every arm · 1 — Emapalumab is usual care beside what is tested
Codes
What other systems call Emapalumab · ClinicalTrials.gg INT001177
- MeSH (NLM) C000644327EmapalumabOne source ClinicalTrials.gov
- UNII (FDA) 3S252O2Z4XEMAPALUMABConfirmed FDA, Wikidata
- RxNorm 2104604One source FDA
- Wikidata Q28209889emapalumabConfirmed FDA, Wikidata
- NCI Thesaurus C127123EmapalumabOne source FDA
- DrugBank DB14724One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000644327 | Emapalumab | One source ClinicalTrials.gov |
| UNII (FDA) | 3S252O2Z4X | EMAPALUMAB | Confirmed FDA, Wikidata |
| RxNorm | 2104604 | — | One source FDA |
| Wikidata | Q28209889 | emapalumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C127123 | Emapalumab | One source FDA |
| DrugBank | DB14724 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.